In a study from our group, IL-8 was the circulating factor most significantly correlated with survival in both a discovery and an independent validation cohort of advanced pancreatic cancer treated with nanoliposomal irinotecan-based II-line chemotherapy [48]. This evidence concerns the gene CXCL8 and pancreatic neoplasm.